Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13447721 | 0.86 | MGLL (0.33) | MGLL | |
| SCHEMBL6699078 | 0.83 | MGLL (0.33) | MGLL | |
| SCHEMBL17777287 | 0.83 | MGLL (0.33) | MGLL | |
| SCHEMBL2570463 | 0.83 | MGLL (0.33) | MGLL | |
| SCHEMBL7924643 | 0.82 | MGLL (0.32) | MGLL | |
| SCHEMBL13347914 | 0.81 | MGLL (0.30) | MGLL | |
| SCHEMBL23619542 | 0.80 | MGLL (0.34) | MGLL | |
| SCHEMBL17664956 | 0.80 | MGLL (0.31) | MGLL | |
| SCHEMBL13989239 | 0.80 | MGLL (0.31) | MGLL | |
| SCHEMBL260599 | 0.80 | MGLL (0.34) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808452-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | NOVO NORDISK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| EP-2627670-A2 | NOVEL N-TERMINALLY MODIFIED INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012049307-A2 | NOVEL N-TERMINALLY MODIFIED INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315797-A1 | Novel N-Terminally Modified Insulin Derivatives | IAPP, INSR, IRS1 | MGLL 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.